Adverse events186

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 186

Type	Event	Organ system	Group	Affected	At risk
other	Muscle spasms	Musculoskeletal and connective tissue disorders	Vismodegib Intermittent Schedule	83	114
other	Muscle spasms	Musculoskeletal and connective tissue disorders	Vismodegib Induction Followed by Intermittent Schedule	94	113
other	Arthralgia	Musculoskeletal and connective tissue disorders	Vismodegib Intermittent Schedule	18	114
other	Arthralgia	Musculoskeletal and connective tissue disorders	Vismodegib Induction Followed by Intermittent Schedule	16	113
other	Myalgia	Musculoskeletal and connective tissue disorders	Vismodegib Intermittent Schedule	18	114
other	Myalgia	Musculoskeletal and connective tissue disorders	Vismodegib Induction Followed by Intermittent Schedule	12	113
other	Back pain	Musculoskeletal and connective tissue disorders	Vismodegib Intermittent Schedule	7	114
other	Back pain	Musculoskeletal and connective tissue disorders	Vismodegib Induction Followed by Intermittent Schedule	7	113
other	Dysgeusia	Nervous system disorders	Vismodegib Intermittent Schedule	76	114
other	Dysgeusia	Nervous system disorders	Vismodegib Induction Followed by Intermittent Schedule	75	113
other	Ageusia	Nervous system disorders	Vismodegib Intermittent Schedule	13	114
other	Ageusia	Nervous system disorders	Vismodegib Induction Followed by Intermittent Schedule	14	113
other	Headache	Nervous system disorders	Vismodegib Intermittent Schedule	10	114
other	Headache	Nervous system disorders	Vismodegib Induction Followed by Intermittent Schedule	14	113
other	Alopecia	Skin and subcutaneous tissue disorders	Vismodegib Intermittent Schedule	72	114
other	Alopecia	Skin and subcutaneous tissue disorders	Vismodegib Induction Followed by Intermittent Schedule	73	113
other	Pruritus	Skin and subcutaneous tissue disorders	Vismodegib Intermittent Schedule	8	114
other	Pruritus	Skin and subcutaneous tissue disorders	Vismodegib Induction Followed by Intermittent Schedule	13	113
other	Actinic keratosis	Skin and subcutaneous tissue disorders	Vismodegib Intermittent Schedule	10	114
other	Actinic keratosis	Skin and subcutaneous tissue disorders	Vismodegib Induction Followed by Intermittent Schedule	8	113

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01815840/events

API reference For AI assistants

Adverse events186

Sources 3

Read this list from software.